A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease

Table 3 Summary of results in patients on placebo

Measurements	Mean pre-placebo	Mean post-placebo	p value
Systolic BP (mmHg)	135 ± 13	128 ± 17	0.19
Diastolic BP (mmHg)	82 ± 7	78 ± 11	0.27
Total cholesterol (mmol/l)	4.31 ± 0.85	4.50 ± 1.06	0.57
HDL (mmol/l)	1.05 ± 0.34	1.06 ± 0.35	0.96
LDL (mmol/l)	2.42 ± 0.70	2.50 ± 0.96	0.80
Triglycerides (mmol/l)	2.11 ± 1.15	2.39 ± 1.42	0.55
HbA1c (mmol/mol)	50 ± 15	51 ± 15	0.92
Fructosamine (μmol/l)	257 ± 53	266 ± 64	0.67
HOMA-IR	3.1 ± 1.8	3.0 ± 1.4	0.86
∆RI-GTN (%)	24 ± 7	23 ± 6	0.58
∆RI-Salb (%)	9 ± 6	9 ± 6	0.98
sVCAM-1 (ng/ml)	705 ± 423	722 ± 423	0.91
cGMP (pmol/l)	177 ± 46	177 ± 59	0.98
Blood glutathione ratio	20 ± 12	21 ± 9	0.65
TAC (mM Asc [AEAC])	0.43 ± 0.06	0.44 ± 0.07	0.62
hsCRP (mg/l)	3.2 ± 5.3	2.7 ± 2.7	0.72
ALT (iu/l)	51 ± 19	49 ± 26	0.86
AST (iu/l)	40 ± 15	41 ± 17	0.90
Mode ASQ (C²m)	99 ± 10	95 ± 13	0.44

VSL#3^® treated group n = 19; placebo treated group n = 16. Data expressed as mean and standard deviation. Four cGMP values were not measurable (3 from placebo group and 1 from VSL#3^® group). HOMA-IR missing 1 value from each treatment group as insulin levels were outside the HOMA calculator range. HbA1c in the placebo group had one missing value. LDL cholesterol had missing data on 1 patient from placebo group and 1 from VSL#3^® group as triglycerides were > 4.5 mmol/l which preclude LDL cholesterol calculation. SBP and DBP values were missing after intervention on 1 patient in the placebo group. Nineteen patients had completed ASQ (10 in VSL#3^® group and 11 in placebo group). Missing data were excluded from respective analyses

ISSN: 1471-230X